At Pentabase, we strive to help you with your needs. Call us or send us an e-mail, and one of our experts will get in touch with you.
PentaBase is a knowledge-based Danish pharmacogenomics company founded and managed by researchers and located in the heart of Denmark. We specialise in custom oligonucleotide production and the development of in vitro diagnostic assays for real-time PCR with a special focus on the detection of somatic mutations in cancer and COVID-19.
For more than 10 years, PentaBase has created products for researchers and medical professionals exploring new treatments and helping patients worldwide.
Our products are given unique abilities in the analysis and manipulation of genetic material with our proprietary technology, INAs® (Intercalating Nucleic Acids). Medical professionals and researchers use these features to help treat diseases and acquire new knowledge. We believe in open-platform designs and strive to make our products compatible with basic instruments used in molecular biology facilities worldwide.
We continuously work with researchers and the research community to develop new products. We are always open to new collaborations. Are you challenged in genetic analysis - talk to us.
We strive to use our proprietary DNA technologies and our knowledge about real-time PCR to offer our customers the best service possible. We aim to combine fast delivery of superior quality products with optimal support before, during, and after the purchase.
We believe in helping the next generation of pioneers and we prioritise a close relationship with local biotech research communities for the benefit of all parties. Our collaboration with the research communities is a valuable way of getting access to the newest knowledge and finding candidates for positions at PentaBase.
Innovation and creativity are central parts of our organisation, and we consider ourselves front-runners within innovations for real-time PCR applications. We continuously use our strong knowledge about real-time PCR and our proprietary DNA technologies to develop new products that improve or disrupt existing technologies.
Our mission is based on our knowledge and proprietary DNA platform technologies, to offer scientists and researchers better and more precise tools for analyses of genetic.
Enable the detection and monitoring of treatable diseases as early and as efficiently as possible.
Broaden and improve the use of personalized treatment of genetic diseases and cancer.
Reduce the number of false-negative samples by improving sensitivity and reducing the complexity of genetic analyses.